279 related articles for article (PubMed ID: 25832652)
21. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
22. Emerging treatments for classical myeloproliferative neoplasms.
Vannucchi AM; Harrison CN
Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
[TBL] [Abstract][Full Text] [Related]
23. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
24. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Bose P; Verstovsek S
Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Verstovsek S
Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
[TBL] [Abstract][Full Text] [Related]
27. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
28. [The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].
Yang AY; Liu JQ; Cai YN; Fang MY; Yang L; Chen M; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1003-1007. PubMed ID: 32023730
[No Abstract] [Full Text] [Related]
29. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
Guglielmelli P; Rotunno G; Bogani C; Mannarelli C; Giunti L; Provenzano A; Giglio S; Squires M; Stalbovskaya V; Gopalakrishna P; Vannucchi AM;
Br J Haematol; 2016 Jun; 173(6):938-40. PubMed ID: 26303809
[No Abstract] [Full Text] [Related]
30. The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.
Cardoso BA; Belo H; Barata JT; Almeida AM
PLoS One; 2015; 10(12):e0143897. PubMed ID: 26623653
[TBL] [Abstract][Full Text] [Related]
31. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
Verstovsek S; Yeleswaram S; Hou K; Chen X; Erickson-Viitanen S
Hematol Oncol; 2018 Oct; 36(4):701-708. PubMed ID: 30105794
[TBL] [Abstract][Full Text] [Related]
32. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
33. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
35. Safety evaluation of ruxolitinib for treating myelofibrosis.
Galli S; McLornan D; Harrison C
Expert Opin Drug Saf; 2014 Jul; 13(7):967-76. PubMed ID: 24896661
[TBL] [Abstract][Full Text] [Related]
36. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
37. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
Heine A; Held SA; Daecke SN; Wallner S; Yajnanarayana SP; Kurts C; Wolf D; Brossart P
Blood; 2013 Aug; 122(7):1192-202. PubMed ID: 23770777
[TBL] [Abstract][Full Text] [Related]
38. Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
Curran SA; Shyer JA; St Angelo ET; Talbot LR; Sharma S; Chung DJ; Heller G; Hsu KC; Betts BC; Young JW
Cancer Immunol Res; 2017 Jan; 5(1):52-60. PubMed ID: 27923824
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the management of patients with myelofibrosis.
Manea PJ
Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
[TBL] [Abstract][Full Text] [Related]
40. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
